Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   HEPATITIS MONTHLY   APRIL 2011 , Volume 11 , Number 4 (33); Page(s) 240 To 246.
 
Paper: 

THE OPTIMAL DOSE OF RIBAVIRIN FOR CHRONIC HEPATITIS C: FROM LITERATURE EVIDENCE TO CLINICAL PRACTICE

 
 
Author(s):  ABENAVOLI LUDOVICO*, MAZZA MARTA, ALMASIO PIERO L.
 
* DEPARTMENT OF EXPERI¬MENTAL AND CLINICAL MEDICINE, UNIVERSITY MAGNA GRACIA, VIALE EUROPA, 88100, CATANZARO, ITALY
 
Abstract: 

Approximately 170 million people worldwide are chronically infected by hepatitis C virus (HCV), which can result in progressive hepatic injury and fibrosis, culminating in cirrhosis and end-stage liver disease. The benchmark therapy for untreated HCV patients is a combination of pegylated interferon-alpha (PEG-IFN) and ribavirin (RBV). Several studies have suggested several potential new approaches to improve HCV therapy-optimization of the dose and duration of RBV therapy, accompanied by careful clinical management, is crucial in ensuring the greatest likelihood of a long response to therapy. RBV causes serious side effects, but in clinical practice, there are no alternatives for the treatment of HCV infection. Based on our results, weight-based doses of RBV are advantageous for genotype 1-infected patients, but its success in genotype 2- and 3-infected patients is unknown, particularly for shorter treatment durations.

 
Keyword(s): HEPATITIS C VIRUS, RIBAVIRIN, DOSE-RESPONSE
 
References: 
  • ندارد
 
  pdf-File tarjomyar Yearly Visit 75
 
Latest on Blog
Enter SID Blog